Medpace Holdings Inc (NASDAQ: MEDP) is a contract research organization (CRO) that provides clinical development services to biopharmaceutical, biotechnology, and medical device companies. The company generates revenue by conducting outsourced clinical trials and related drug development services on a fee-for-service basis under contracts with pharmaceutical and biotech sponsors. Medpace is listed on the Nasdaq Global Select Market and filed its 10-K for fiscal year ended December 31, 2025 on February 10, 2026. The filing confirms Medpace operates as a well-known seasoned issuer, indicating a material public market capitalization as of June 30, 2025.

Revenue model

Fee-for-service contracts with biopharmaceutical, biotechnology, and medical device sponsors for outsourced clinical trial management and drug development services.

Products and services

Clinical development and contract research services for pharmaceutical, biotechnology, and medical device companies, including clinical trial management and related regulatory support services.

Customers and end markets

Biopharmaceutical, biotechnology, and medical device companies requiring outsourced clinical development services.

Value-chain role

Outsourced clinical trial execution and drug development services provider, sitting between drug sponsors and clinical trial endpoints in the pharmaceutical development value chain.

Source: SEC 10-K, filed 2026-02-10

Industry: Services-Commercial Physical & Biological Research Peers: 10X Genomics Inc Azenta Inc Bruker Corp Charles River Laboratories International Inc Syneos Health, Inc. Maravai LifeSciences Holdings Inc Repligen Corp Sotera Health Co Thermo Fisher Scientific Inc